Plexium Inc, a developer of protein degrading therapeutics directed towards historically challenging drug targets, has secured $35 million in financing. Lux Capital and Pivotal BioVentures led the round.
Source: Press Release
Plexium scores $35m
Plexium Inc, a developer of protein degrading therapeutics directed towards historically challenging drug targets, has secured $35 million in financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: